Traynor Capital Management Inc. increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,443 shares of the medical research company’s stock after buying an additional 270 shares during the period. Traynor Capital Management Inc.’s holdings in Amgen were worth $531,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Oakworth Capital Inc. boosted its stake in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares during the last quarter. Delta Asset Management LLC TN boosted its stake in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares during the last quarter. Capital Advisors Ltd. LLC boosted its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares during the last quarter. Vigilant Capital Management LLC boosted its stake in shares of Amgen by 2.6% in the second quarter. Vigilant Capital Management LLC now owns 1,283 shares of the medical research company’s stock worth $195,000 after buying an additional 33 shares during the last quarter. Finally, Calamos Wealth Management LLC purchased a new stake in shares of Amgen during the second quarter worth about $202,000. Institutional investors and hedge funds own 79.15% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.48% on Monday, reaching $168.31. The company had a trading volume of 1,628,204 shares. The firm has a market cap of $125.96 billion, a P/E ratio of 17.22 and a beta of 0.94. Amgen Inc. has a one year low of $139.02 and a one year high of $176.85. The company has a 50-day moving average price of $170.75 and a 200-day moving average price of $161.82.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.58 billion. During the same quarter last year, the firm earned $2.57 EPS. Amgen’s revenue for the quarter was up 5.9% compared to the same quarter last year. On average, analysts expect that Amgen Inc. will post $11.35 earnings per share for the current fiscal year.
A number of analysts have recently issued reports on the company. Leerink Swann reiterated a “hold” rating on shares of Amgen in a report on Saturday, September 17th. Credit Suisse Group AG set a $206.00 target price on Amgen and gave the stock a “buy” rating in a report on Saturday, September 17th. Vetr upgraded Amgen from a “hold” rating to a “buy” rating and set a $159.50 target price for the company in a report on Monday, June 13th. Jefferies Group reiterated a “buy” rating and set a $187.00 target price on shares of Amgen in a report on Wednesday, July 13th. Finally, Robert W. Baird restated a “neutral” rating and issued a $157.00 price target on shares of Amgen in a report on Friday, July 15th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $184.94.
In other news, VP Annette Louise Such sold 3,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.